A Study Assessing Molecular And Clinical Effect Of Nivolumab Or Pembrolizumab In Patients With Gynaecologic Malignancies

Trial Profile

A Study Assessing Molecular And Clinical Effect Of Nivolumab Or Pembrolizumab In Patients With Gynaecologic Malignancies

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer
  • Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 10 Apr 2017 New trial record
    • 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top